Articles
23.10.2017
Pricing and reimbursements for biosimilars

Paul Craddy is proud to be presenting at the Global Pharmaceutical Regulatory Affairs Summit in Prag...

Read more
News
06.10.2017
UK pharma denied legal challenge to drugs bill cap

The Association of British Pharmaceutical Industry has been refused a legal challenge to a cap on th...

Read more
Articles
05.08.2017
Pricing and market access skills

Obtaining market access at the right time and at an appropriate price has become more complex for ph...

Read more
Articles
05.07.2017
No confidential discounts in Germany

Introduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...

Read more
Articles
05.06.2017
New parallel consultation process

A one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...

Read more
Publications
24.05.2017
NICE re-evaluation of oncology drugs

This study investigates NICE's evaluation of existing CDF treatments and its potential impact on fun...

Read more
News
26.04.2017
PMA Perspective Q1 2017

Included in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...

Read more
Articles
05.03.2017
Managed entry agreements

MEAs are also known by other names such as risk-sharing agreements, value-added services, and result...

Read more
Articles
05.01.2017
How NICE is coping with managing the CDF

This process aims to be completely transparent , to enable faster patient access to oncology treatme...

Read more
Articles
21.11.2016
Potential changes to NICE

NICE has recently published a consultation on changes to its appraisal process to "fast track" some ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.